European Lung Cancer Congress 2023 - ESMO Lung Cancer Paradigm Pushes Toward Accessible Care and Improved Telemedicine. This one-day conference will provide a comprehensive, multidisciplinary update on recent clinical advances in lung cancer. Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists, all benefited from the comprehensive programme. IVBH Presents Groundbreaking Data for Early Lung Cancer Detection at the ASCO 2023 Annual Meeting. and Independence in Accredited Continuing Education. Join us to discuss and present new and emerging data on immunoresistance in NSCLC! patients. In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. It is our great pleasure and honor to extend a warm invitation to attend and participate in the IASLC 2023 World Conference on Lung Cancer (#WCLC23) to be held in Singapore from September 9 12, 2023. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS. The field of nonsmall cell lung cancer has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 skipping mutations, RET rearrangements, and ROS1 mutations. 26 May 2023 Awardee Sherene Loi (fourth from left) with Prof Roger Daly (far left), Beate Lackmann (right of Sherene) and the Co-convenors. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. An Presentations will summarize information about ongoing clinical trials of the newest therapies for lung cancer including data on preclinical and early clinical data. This activity was planned by and for the healthcare team and learners will receive 7.50 Interprofessional Continuing Education (IPCE) credits for learning and change. Latest breakthroughs in translational cancer research on show at CSTI We hope you enjoyed the education and the discussions. Annual Conference | Lung Cancer Nursing UK Precision Oncology beyond EGFR/ALK for NSCLC in 2023: Test, Target, Manage, European Lung Cancer Congress 2023: Prof. Martin Reck on why you can`t miss this event, European Lung Cancer Congress 2023: Prof. Noemi Reguart on why you can`t miss this event, European Lung Cancer Congress 2023: What you can expect from this event. }); After completing this activity, the participant will be able to: Name of Ineligible Company(s) / Nature of Relationship(s), Stephen V. Liu, MDDirector, Thoracic Medical Oncology, Director, Phase I Developmental Therapeutics, Associate Professor, Medicine, Activity Co-Director Content Reviewer, Faculty, Advisor-Amgen|Advisor-AstraZeneca AstraZeneca|Advisor-AbbVie|Advisor-BMS|Advisor-Catalyst (Relationship has ended)|Advisor-Daiichi Sankyo, Inc.|Advisor-Eisai|Advisor-Elevation Oncology|Advisor-Genentech, Inc.|Advisor-Gilead Sciences, Inc.|Advisor-Guardant Health|Advisor-Janssen|Advisor-Jazz Pharmaceuticals|Advisor-Merus|Consulting Fee-Merck|Advisor-Novartis Pharmaceuticals|Advisor-Regeneron|Advisor-Sanofi|Advisor-Takeda|Advisor-Turning Point Therapeutics|Grant or research support-Alkermes|Grant or research support-Elevation Oncology|Grant or research support-Genentech, Inc.|Grant or research support-Gilead Sciences, Inc.|Grant or research support-Merck|Grant or research support-Merus|Grant or research support-Nuvalent|Grant or research support-RAPT|Grant or research support-Turning Point Therapeutics, Nagla F. Abdel Karim, MDMedical Oncologist. It is the CME activity providers responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Industry partners: find out how to get involved. Tobacco use is a well-established cause of cancer and contributes to about 1 in 3 cancer deaths. Welcome | Australian Lung Cancer Conference 2023 Welcome Towards 2030 - a decade of transformation in lung cancer On behalf of the Lung Foundation Australia, we warmly invite to you to be part of the 9th Australian Lung Cancer Conference to be held on the beautiful Gold Coast, Queensland from 15-17 February 2023. Contributed May 30, 2023. A medical student with a passion for lung cancer research has been awarded the 2023 Daniel T. O'Connor, M.D. Both onsite and online formats effectively disseminated the latest advances in lung and thoracic malignancies, giving experts from around the world a chance to identify promising new research avenues. Use tab to navigate through the menu items. Researchers examine emerging data demonstrating that functionally distinct arrhythmia classes are associated with radiotherapy dose to discrete cardiac substructures. "Not only did we bring together the foremost experts in the field, but we also witnessed a true synergy of ideas and collaborations that will undoubtedly accelerate progress in cancer research," said the co-convenors in a joint statement. All programs remain, 2023 Cancer Updates GI Cancer Dinner Program, 2023 Community Oncology Educational Discussion Dinner Series TNBC, 2023 Cancer Updates Breast Cancer Dinner Program, 2023 Community Oncology Educational Discussion Dinner Series ER+, 2023 Cancer Updates GU Cancer Dinner Program, 2023 Community Oncology Education Discussion Series October, 2023 Community Oncology Educational Discussion Dinner Series Diagnostics, 2023 Cancer Updates Hematology Dinner Program, 2023 What Changes Monday Morning? IVBH Presents Groundbreaking Data for Early Lung Cancer Detection at Why Attend TTLC 2023? This innovative and state of the art program will feature some of the world's leading lung cancer experts to present the latest research and strategies for the care of lung cancers incorporating data from the major oncologic annual meetings. Gate Repeater - You have previously attended a Gate. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. The 2023 Great Debates and Updates in Lung Cancers is a multi-day, debate-driven conference focusing on the treatment of thoracic oncology. We invite you to join us for the 1st Annual Best of Lung Cancer conference. The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. WCLC 2022 World Conference on Lung Cancer - HealthManagement.org Identify the benefit of CT screening for lung cancer. This symposium is not certified for continuing education credit. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 MOC points in the American Board of Internal Medicines (ABIM) Maintenance of Certification (MOC) program. Repeat histologic evaluation and molecular testing in patients with EGFR-mutant nonsmall cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions. Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients. Integrate a team-based approach in the care of patients with lung cancer. We hope to see you there! The 2023 Texas Lung Cancer Conference Would Not Be Possible Without The Generous Support From Our Sponsors. Welcome | Australian Lung Cancer Conference 2023 Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development. The conference welcomed a stellar line-up of national and international speakers, reporting ground-breaking developments in a range of topics including cancer cell signalling, immunotherapies, precision oncology, systems biology, paediatric cancer and tumour evolution. The ESMO Daily Reporter is the official ESMO newspaper providing live reporting, highlights, critical insights on data presented at ESMO congresses, and expert opinions on controversial topics. Efforts to Effectively Target Rare Oncogenes Propel Progress in Lung Cancer. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve the consistency of pathologic assessment of treatment response. Two keynote speakers, Dr. Kim-Lori Sandler and Dr. Michael Gieske, addressed their respective work and research as it . Home - WCLC 2023 Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer. Surgical resection remains the key treatment modality for early-stage nonsmall cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients. Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC. orating data from the major oncologic annual meetings. Lung and thoracic specialists count on the IASLCs journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. We invite you to join us for the 1st Annual Best of Lung Cancer conference. Stay up to date on all the latest news from WCLC 2023, (click on the dates to add to your calendar), April 14, 2023 (23:59 PST) / April 15, 2023 (15:59 SGT), June 9, 2023 (23:59 PST) / Jun 10, 2023 (15:59 SGT), Be part of the largest international gathering of Lung Cancer Professionals. Learn more. Convention Centre Pl 1. There is also a lack of precise definitions of the degree of pathologic response, including Major Pathologic Response (MPR) or Complete Pathologic Response (CPR). Dr. Basu Roy on Addressing Barriers to Biomarker Testing in Lung Cancer. This two-day CE event will review the latest advances in lung cancer focused on what a medical oncologist needs to know to provide stateofthe art care today. activity, including faculty, planners, reviewers, or others are required to Free oncology conference and content updates weekly. All funding for this site is provided directly by ESMO. Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review. Explain the application of targeted therapy and immunotherapy in the treatment of NSCLC. We have secured a roster of the top lung cancer researchers in the country, all of whom are approachable, energetic, and engaging experts. Market to one of the most unique gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. Describe current standard care for advanced mesothelioma. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Identify nursing strategies for early detection of immune-mediated toxicities. A world-class gathering of leading researchers in cell signalling and cancer research took place in May at the highly anticipated Cell Signalling and its Therapeutic Implications (CSTI) Conference, held on the Mornington Peninsula. Individuals in a position to control the content of this CE This innovative and state of the art program will feature some of the world's leading lung cancer experts to present the latest research and strategies for the care of lung cancers incor. IASLC | International Association for the Study of Lung Cancer Early Registration for WCLC 2023 Is Now Open! 02 Jun, 2023, 11:00 ET. ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC. Describe the role of the patient advocate in clinical research. Thursday, July 19 - Friday, July 21, 2023, JTO Clinical and Research Reports (JTO CRR), IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer, Career Development and Fellowship Committee, Nurses and Allied Health Professionals Committee, Tobacco Control and Smoking Cessation Committee, Learn More About IASLC's Corporate Roundtable, IASLC 2023 World Conference on Lung Cancer | Singapore, https://www.jtocrr.org/article/S2666-3643(23)00072-3/fulltext?rss=yes, https://www.jtocrr.org/article/S2666-3643(23)00073-5/fulltext?rss=yes, https://www.jto.org/article/S1556-0864(23)00578-6/fulltext?rss=yes, https://www.jtocrr.org/article/S2666-3643(23)00071-1/fulltext?rss=yes. We're delighted to announce the launch of our 2023 conference scheduled to take place on 11 and 12 May 2023 at the Eastside Rooms, Birmingham. 2023 Targeted Therapies of Lung Cancer Meeting. Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer. selling, re-selling, or distributing healthcare products used by or on TheELCC 2023will take place at the Bella Center Copenhagen, Denmark. Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer. IVBH. Home | Great Debates & Updates in Lung Cancers There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on modern bronchoscopy, proton beam radiation, minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy. Free registration for all healthcare providers, Expert video sessions that present the most clinically relevant data, research, and clinical strategies, Enduring video content for watching at your leisure, Virtual networking with peers, colleagues, and medical professionals, Virtual access to the latest industry information and resources, 2023 by Total Health Information Services, LLC. mitigated prior to the commencement of the activity. IASLC | International Association for the Study of Lung Cancer This accolade recognises excellence in translational research and was awarded to Professor Sherene Loi of the Peter MacCallum Cancer Centre. We invite you to join us for the 1st Annual Best of Lung Cancer conference. 2023 International Association for the Study of Lung Cancer IASLC WCLC 2023 | Privacy Notice, It is our great pleasure and honor to extend a warm invitation to attend and participate in, 2023 World Conference on Lung Cancer (#WCLC23) to be held in Singapore from, Education, Tobacco Control & Patient Advocate Awards. The Texas Lung Cancer Conference is more than a rehash of the available data it is an opportunity to understand the reasoning behind the trials and the best approach to patient care. Fort Myers, Fla., June 1, 2023 - Florida Cancer Specialists & Research Institute, LLC (FCS) physicians are presenting the outcomes of 23 clinical trials, the majority being Phase 1, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2 - 6 in Chicago, Illinois. Immunotherapy Advances Drive Progress in Lung Cancer Treatment. ASCO Meetings JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. View our latest updates. Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC. March 30 - April 1, 2023 ACL Live at the Moody Theater in Austin, Texas @TLCconference #TexasLung23 Endorsed by Accredited by Presented by TLC Conference Chairs We are excited to invite you to join us at the 1st Annual Texas Lung Cancer Conference in Austin, TX at the historic Austin City Limits. MedStar Health, D.C. The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer. ADAURA Raises Questions About Optimal Use of Adjuvant EGFR TKIs in NSCLC. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The event was made possible thanks to the generous support of key sponsors, the Melbourne Convention Bureau and Business Event Victoria, whose commitment to supporting events in Victoria played a pivotal role in the conference's success. 2023 Best of Lung Cancer Conference | Total Health For inquiries please emails us at TexasLung@IDEOlogyHealth.com. Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer. Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC. including lung cancer evolution and environmental factors (Professor Charles Swanton, Francis Crick Institute), new . Antibody-drug conjugates appear to have the most activity in those with nonsmall cell lung cancer and HER2 expression. Join us as we look ahead at lung cancer nursing, exploring ways to ensure the workforce is fit for the future and asking where we go from here. Necessary cookies enable core functionality. Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer. Home - 2023 Targeted Therapies of Lung Cancer Meeting Save the date for ttlc 2024! Discuss management of immune-mediated toxicities. disclose all relevant financial relationships with ineligible companies. In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. For more detailed information on the cookies we use, please check our Privacy Policy. The Universal Activity Number for this program is UAN# JA4008151-0000-23-030-L05-P. Hotel arrangements can be made online at:book.passkey.com/go/MedstarHealth2023. Describe the approved use of tumor treating fields. 2023 Best of Lung Cancer Conference - Cvent Identify best practices in biomarker testing and the utilization of biomarkers to drive treatment decisions for patients with lung cancer. 8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide. Future of Frontline EGFR+ NSCLC Features TKI, Chemo Combos and Improved Molecular Profiling. If the FDAs Oncologic Drugs Advisory Committee meeting held on February 10, 2022, was any indication, the days of applying foreign single country or region data to support regulatory approval are gone; instead, regulatory decisions are headed toward the need for regional consistency through multiregional clinical trials, which could help the United States overcome the persistent underrepresentation of racial and ethnic minorities in drug development. Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung Cancer. Marks, MDHematologist & Medical Oncologist, Michael E. Menefee, MDAssistant Professor, Medicine, Drew Moghanaki, MD, MPHProfessor of Radiation Oncology, Consulting Fee-Astra Zeneca Astra Zeneca|Advisor-Merck (Relationship has ended), Nitika Paudel, MD, PhDRadiation Oncologist, Radiation Medicine; Assistant Professor, Radiation Medicine, Speakers Bureau-Astra Zeneca Astra Zeneca (Relationship has ended), Zofia Piotrowska, MD, MHSMedical Oncologist, Assistant Professor, Medicine, Joshua E. Reuss, MDThoracic Medical Oncologist; Assistant Professor, Medicine, Membership on Advisory Committees or Review Panels, Board Membership, etc.-Mirati Therapeutics (Relationship has ended). Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. From Awareness to Action: Championing Diversity, Equity, and Inclusion in Cancer Care, Hilton Fort Lauderdale Marina Hotel, South Florida, Cheyenne Mountain Resort Colorado Springs, 2023 by Total Health Information Services, LLC, 2023 registration is now open. D.C. Lung Cancer Conference 2023 - MedStar Health - Continuing ineligible company is any entity whose primary business is producing, marketing, You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Home - 2023 Targeted Therapies of Lung Cancer Meeting Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer. Lara is now a student in the UC Davis School of Medicine, which, for him . PER Winter Lung Cancer Conference - OncLive . Neoadjuvant therapies have unique advantages and opportunities in lung cancer and need further investigation. Dr. Raez on the Potential Utility of Cemiplimab in NSCLC. Sessions will cover the basics (What is NGS?) and the advanced (How can we predict and prevent acquired resistance?), making this conference appropriate for all levels of training and experience. Describe the benefit of immunotherapy in the treatment of small cell lung cancer. Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Describe current and evolving management strategies for patients with localized and locally advanced lung cancer. Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III nonsmall cell lung cancer based on the results of the phase 3 PACIFIC trial. Home - LALCA 2023 MOC Participation Threshold Memorial Research Grant. Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with nonsmall cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval. Professor Daly said, The line-up of local, national and international speakers was amazing! Kuoni Global Travel Services Congresshas been appointed as official housing agency for the ELCC 2023, ESMO COVID-19 regulations to access the congress, Contact information for the event organisers, Follow #ELCC23 on Facebook, Twitter, LinkedIn, Instagram and YouTube. Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2, Early Breast Cancer, Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL, Dr Garcia-Manero on Luspatercept in Lower-Risk MDS, Dr Zeidan on Imetelstat in Lower-risk MDS, OncLive National Fellows Forum: Lung Cancer 2023, Join us in Chicago for Giants of Cancer Care, | Join us in Chicago for Giants of Cancer Care. Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III nonsmall cell lung cancer. CARIBOU, Maine On Thursday, May 18 Cary Medical Center hosted the virtual conference "Turning the Tide on Lung Cancer" highlighting the importance of low dose CT lung cancer screening. Market to one of the most unique gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. The schedule consists of both in-person and virtual meetings, be sure to check the access type. Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. RNA-Based NGS Offers the Potential to Identify More Patients With Rare Alterations in NSCLC. Join us in Singapore for the 2023 World Conference on Lung Cancerthe ultimate event for medical professionals like you. Lung Cancer Conference 2023, 10/7/2023 7:30:00 AM - 10/7/2023 5:30:00 PM, This one-day conference will provide a comprehensive, multidisciplinary update on recent clinical advances in lung cancer. The schedule consists of both in-person and virtual meetings, be sure to check the access type. Overall, the test correctly revealed cancer 66% of the time (Stock image) A blood test that can detect more than 50 different types of cancer has shown promise . This conference is brought to you byIDEOlogy Health. Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance. 'Turning the Tide on Lung Cancer' conference highlights the importance ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting .
Shimano Rear Derailleur, Eccv Conference Ranking, Brio Collapsing Bridge, Hyperkin Hdtv Cable For Ps2/ps1, Cardo Packtalk Bold With Earbuds, Articles L